China’s pharmaceutical sector moves into the big leagues as a global innovation powerhouse
The China Pharmaceutical Innovation and Invention Index, a new gauge, highlights top drug makers on the mainland for the first time
China is gaining a solid reputation as a pharmaceutical innovation hub, shifting from a copycat drug maker to one whose infrastructure and research and development capabilities rival global pharmaceutical behemoths, according to a global consultancy.
US-based SAI MedPartners and its unit Idea Pharma recently launched a new index with the aim of highlighting Chinese drug makers and recognising their shift from generics to “true” innovation.
The consultancy released the China Pharmaceutical Innovation and Invention Index (CPIII) on December 7 as a stand-alone ranking for the first time, after 14 years of publishing a global pharmaceutical innovation index.
